Evidence map›Paper›PMID 41410191›Full record

ArticleJournal of evidence-based medicine2025

Patient Version of Guideline for Fibromyalgia (2025 Edition).

Zhiling Zhang, Pengxiang Zhou, Na He, Ziyang Wu, Shining Bo, Chao Chen, Shuhong Chi, Ning Hou, Ji Hu, Fanbo Jing and 29 more

Abstract read
In one paragraph

Article in Journal of evidence-based medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Zhiling ZhangDepartment of Pharmacy, Peking University Third Hospital, Beijing, China.
Pengxiang ZhouDepartment of Pharmacy, Peking University Third Hospital, Beijing, China.
Na HeDepartment of Pharmacy, Peking University Third Hospital, Beijing, China.
Ziyang WuDepartment of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Shining BoDepartment of Critical Care Medicine, Peking University Third Hospital, Beijing, China.
Chao ChenDepartment of Pharmacy, The Sixth Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China.
Shuhong ChiDepartment of Rheumatology and Immunology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Ning HouDepartment of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Ji HuPatient Representative for Fibromyalgia.
Fanbo JingDepartment of Pharmacy, Affiliated Hospital of Qingdao University, Qingdao, China.
Baohua LiNursing Department, Peking University Third Hospital, Beijing, China.
Ling LiDepartment of Rheumatology and Immunology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China.
Shuiqing LiDepartment of Pain Medicine, Peking University Third Hospital, Beijing, China.
Yanni LiPatient Representative for Fibromyalgia.
Yang LinDepartment of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Qipeng LuoDepartment of Pain Medicine, Peking University Third Hospital, Beijing, China.
Jiahui MaiPatient Representative for Fibromyalgia.
Rong MuDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China.
Ronghui OuyangPatient Representative for Fibromyalgia.
Wangjun QinDepartment of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
Rong ShaoInstitute of Regulatory Science, China Pharmaceutical University, Nanjing, Jiangsu, China.
Jianghua ShenDepartment of Pharmacy, Beijing Xuanwu Hospital, Capital Medical University, Beijing, China.
Xiaoying SunDepartment of Rheumatology and Immunology, Peking University First Hospital, Beijing, China.
Tianlin WangDepartment of Pharmacy, Medical Supplies Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Junyan WuDepartment of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Han XieDepartment of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of the Medical School of Nanjing University, Nanjing, Jiangsu, China.
Xiaoyan XuDepartment of Rheumatology and Immunology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Yingying YanDepartment of Pharmacy, Peking University Third Hospital, Beijing, China.
Kehu YangEvidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China.
Zhongqiang YaoDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China.
Chaoqun YeRehabilitation Medicine Department, Air Force Medical Center, Beijing, China.
Yonggui YuanDepartment of Psychiatry and Psychology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China.
Jintao ZhuPatient Representative for Fibromyalgia.
Rongsheng ZhaoDepartment of Pharmacy, Peking University Third Hospital, Beijing, China.
Daying ZhangDepartment of Pain Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Dongfeng LiangDepartment of Rheumatology and Immunology, The Sixth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Xiaofeng ZengDepartment of Rheumatology and Immunology, Peking Union Medical College Hospital, Beijing, China.
Bifa FanDepartment of Pain Medicine, China-Japan Friendship Hospital, Beijing, China.
Suodi ZhaiDepartment of Pharmacy, Peking University Third Hospital, Beijing, China.

Funding

China Society for Drug Regulation 2024-Z-Y-001National Natural Science Foundation of China 72304008
6 · The paper itself

Abstract

objectiveTo develop an evidence-based patient version of guideline (PVG) for fibromyalgia, aiming to improve patients' understanding of disease symptoms and therapeutic options and to enhance their self-management abilities.

methodsFollowing the World Health Organization Handbook for Guideline Development (2014), a multidisciplinary working group was established, including patient representatives, physicians, pharmacists, nurses, and methodologists. The process comprised (a) systematic retrieval of clinical practice guidelines and expert consensus statements to establish the evidence base; (b) integration of large language models (LLMs) with expert review to identify and refine key patient-centered concerns; (c) a three-round Delphi consensus guided by the Grading of Recommendations Assessment, Development and Evaluation approach to finalize clinical questions and formulate recommendations; and (d) evaluation of understandability using the Patient Education Materials Assessment Tool for Print Materials (PEMAT-P).

resultsThe final PVG covers 13 clinical questions across seven domains, including disease awareness, diagnostic evaluation, pharmacological and non-pharmacological interventions, and long-term management. All recommendations were rated as strong. The guideline emphasizes the importance of pharmacological management, emotional regulation, and exercise in the comprehensive management of fibromyalgia. The PEMAT-P assessment showed an understandability score of 100%.

conclusionsDeveloped collaboratively by a multidisciplinary team and patient representatives, this PVG is based on 13 evidence-based fibromyalgia guidelines. Combining LLMs with expert review enhanced question generation and readability. The PVG provides a practical and accessible tool to support early self-management in fibromyalgia.

Indexed as

FibromyalgiaPractice Guidelines as TopicConsensusDelphi TechniqueEvidence-Based MedicineHumansPatient Education as TopicDevelopment and Evaluation (GRADE)fibromyalgiaGrading of Recommendations Assessmentlarge language modelspatient version of guideline

Identifiers

PMID41410191
PMCPMC12750489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.